Posology: Avaxim 80 U Pediatric: Paediatric population: Primary-vaccination: Primary vaccination is achieved with one vaccine dose of 0.5 mL.
Booster: One booster dose of 0.5 mL is recommended in order to provide long-term protection. This booster dose will preferably be administered 6 to 36 months following the primary vaccination dose, but administration will be possible until 7 years after this primary vaccination.
Available data on vaccination with AVAXIM 80 U PEDIATRIC show that after the two doses of the initial vaccination schedule, no other booster vaccination is necessary in immunocompetent individuals, which is in agreement with the official recommendations.
Avaxim 160 U: The recommended dosage for subjects from 16 years of age is 0.5 ml. The initial protection is obtained after one single injection.
In order to obtain a long-term protection against infections caused by the Hepatitis A virus, in adolescents from 16 years of age and in adults, a second dose (booster) should be administered, preferably between 6 and 12 months after the first vaccination and can be administered up to 36 months after the first vaccination (see Pharmacology: Pharmacodynamics under Actions). It is estimated that anti-HAV antibodies persist several years (beyond 10 years) after the second dose (booster).
This vaccine can also be administered as a booster dose of the hepatitis A vaccination in subjects from 16 years of age who received a first injection with the combined typhoid fever (Vi purified polysaccharide) and hepatitis A (inactivated) vaccine between 6 and 36 months earlier.
Method of administration: This vaccine must be administered by the intramuscular route (IM).
The recommended injection site is the deltoid region.
In exceptional cases, the vaccine may be administered by the subcutaneous route in patients with thrombocytopenia or in patients at risk of haemorrhage.
The vaccine should not be administered into the buttocks because of the varying amount of fat tissue in this region, that may contribute to variability in effectiveness of the vaccine.
Do not inject by the intravascular route: ensure that the needle does not penetrate a blood vessel.
Do not inject by the intradermal route.
Avaxim 160 U: See Special precautions for disposal and other handling under Cautions for Usage for the instructions on preparation.